Herpes Vaccine HSV529 Shows Favorable Results in Phase 1 Trial - Contagionlive.com

Herpes Vaccine HSV529 Shows Favorable Results in Phase 1 Trial  Contagionlive.com

In the first-in-human trial of the replication-defective HSV529, the vaccine was well-tolerated and elicited antibody and T-cell responses in HSV seronegative ...